Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine

Ahmed, Kawther K.; Geary, Sean M.; Salem, Aliasger K.

doi:10.1016/j.xphs.2015.11.042

Cited by 23 publications

(25 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many polymeric particulate systems have been engineered to deliver antigen and adjuvant to APCs, namely dendritic cells, for cancer vaccination. Both micro- and nanoparticles synthesized from poly(lactic- co- glycolic acid (PLGA), a biodegradable polymer that has been used for multiple FDA-approved devices, have been extensively studied for cancer vaccine delivery by encapsulating peptide antigen and adjuvant 27–32 . PLGA particles encapsulating peptide antigen and adjuvant have been found to induce a much stronger anti-tumor immune response compared to soluble antigen and adjuvant 30,33 .…”

Section: Antigen Presenting Cells (Apc)mentioning

confidence: 99%

Polymeric micro- and nanoparticles for immune modulation

et al. 2019

View full text Add to dashboard Cite

New advances in biomaterial-based approaches to modulate the immune system are being applied to treat cancer, infectious diseases, and autoimmunity. Particulate systems are especially well-suited to deliver immunomodulatory factors to immune cells since their small size allows them to engage cell surface receptors or deliver cargo intracellularly after internalization. Biodegradable polymeric particles are a particularly versatile platform for the delivery of signals to the immune system because they can be easily surface-modified to target specific receptors and engineered to release encapsulated cargo in a precise, sustained manner. Micro- and nanoscale systems have been used to deliver a variety of therapeutic agents including monoclonal antibodies, peptides, and small molecule drugs that function to activate the immune system against cancer or infectious disease, or suppress the immune system to combat autoimmune diseases and transplant rejection. This review provides an overview of recent advances in the development of polymeric micro- and nanoparticulate systems for the presentation and delivery of immunomodulatory agents targeted to a variety of immune cell types including APCs, T cells, B cells, and NK cells.

show abstract

Section: Antigen Presenting Cells (Apc)mentioning

confidence: 99%

Polymeric micro- and nanoparticles for immune modulation

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The efficacy of particulate delivery systems to deliver cancer vaccines comprised of antigen and adjuvant has been investigated in various studies [87,[89][90][91][92][93][94][95][96][97][98][99][100][101][102]. These studies − Delayed the growth of GL261 glioma intracranially implanted in mice.…”

Section: Functionalised Cnts As Cancer Vaccine Delivery Systemmentioning

confidence: 99%

Application of carbon nanotubes in cancer vaccines: Achievements, challenges and chances

Hassan

Diebold

Smyth

et al. 2019

Journal of Controlled Release

View full text Add to dashboard Cite

Tumour−specific, immuno−based therapeutic interventions can be considered as safe and effective approaches for cancer therapy. Exploitation of nano−vaccinology to intensify the cancer vaccine potency may overcome the need for administration of high vaccine doses or additional adjuvants and therefore could be a more efficient approach. Carbon nanotube (CNT) can be described as carbon sheet(s) rolled up into a cylinder that is nanometers wide and nanometers to micrometers long. Stemming from the observed capacities of CNTs to enter various types of cells via diversified mechanisms utilising energy−dependent and/or passive routes of cell uptake, the use of CNTs for the delivery of therapeutic agents has drawn increasing interests over the last decade. Here we review the previous studies that demonstrated the possible benefits of these cylindrical nano−vectors as cancer vaccine delivery systems as well as the obstacles their clinical application is facing.

show abstract

“…71–73 Another advantage of using PLGA polymers is that they can be processed into a range of shapes and sizes and are compatible with a wide variety of organic solvents. 74 PLGA-based platforms such as microparticles can be readily co-loaded with distinct biomolecules 75 or drugs 76 and have been shown to be capable of differential release kinetics of drugs from the same particle. 76 Finally, PLGA is highly tunable with respect to molecular weight, functionalized end groups and lactide:glycolide ratios.…”

Section: -Fu-loaded Plga Formulationsmentioning

confidence: 99%

Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil

Leelakanok¹,

Geary²,

Salem³

2018

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

5-fluorouracil (5-FU) is a chemotherapeutic agent that has been used for the treatment of a variety of malignancies since its initial introduction to the clinic in 1957. Owing to its short biological half-life, multiple dosings are generally required to maintain effective 5-FU plasma concentrations throughout the therapeutic period. Clinical studies have shown that continuous 5-FU administration is generally superior to bolus injection as exhibited by lower toxicities and increased therapeutic efficacy. Optimal therapeutic efficacy, however, is often compromised by the limiting therapeutic index. Whilst oral formulations are also used, these suffer from the drawbacks of variable bioavailability and first-pass metabolism. As a result, sustained release formulations of 5-FU have been investigated in an effort to mimic the kinetics of continuous infusion particularly for situations where local delivery is considered appropriate. The biocompatible, biodegradable, and highly tunable synthetic polymer, poly(d,l-lactide-co-glycolide) (PLGA), is widely used as a vector for sustained drug delivery, however, issues such as insufficient loading and inappropriate burst release kinetics have dogged progress into the clinic for small hydrophilic drugs such as 5-FU. This review provides introductory information about the mechanism of action, pharmacokinetic and physicochemical properties, and clinical use of 5-FU that have contributed to the development of PLGA-based 5-FU release platforms. In addition, this review provides information on fabrication methods used for a range of 5-FU-loaded PLGA formulations and discusses factors affecting the release kinetics of 5-FU as well as the in vitro and in vivo antitumor or antiproliferative efficacy of these platforms.

show abstract

Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine

Cited by 23 publications

References 46 publications

Polymeric micro- and nanoparticles for immune modulation

Polymeric micro- and nanoparticles for immune modulation

Application of carbon nanotubes in cancer vaccines: Achievements, challenges and chances

Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil

Contact Info

Product

Resources

About